Citius Oncology (CTOR) closed a $9 million public offering of shares and warrants.
The company sold almost 6.82 million shares and related warrants at $1.32 apiece.
Proceeds will support Lymphir commercialization, including license payments, and be used for working capital and general corporate purposes, the company said Thursday in a statement.
Citius Oncology is a majority-owned subsidiary of Citius Pharmaceuticals (CTXR).
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.